| trametinib and dabrafenib vs dabrafenib | No demonstrated result suggested death (overall survival) by 37% (not demonstrated) suggested progression or death (progression free survival PFS) by 37% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | aaa | no data | | recurrence free survival | no data | | death (overall survival) | 0.63 [0.42 0.94] | p=0.04 | 0 | 423 | 1 | COMBI-D (Long), | | progression or death (progression free survival PFS) | 0.63 [0.50 0.80] | p=0.04 | 0 | 405 | 2 | Flaherty,COMBI-D (Long), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| trametinib and dabrafenib vs placebo | No demonstrated result suggested aaa by 49% (not demonstrated) suggested death (overall survival) by 43% (not demonstrated) suggested progression or death (progression free survival PFS) by 53% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | aaa | 0.51 [0.40 0.65] | p=0.04 | 0 | -18 | 1 | COMBI-AD, | | recurrence free survival | no data | | death (overall survival) | 0.57 [0.42 0.78] | p=0.04 | 0 | -18 | 1 | COMBI-AD, | | progression or death (progression free survival PFS) | 0.47 [0.39 0.57] | p=0.04 | 0 | -18 | 1 | COMBI-AD, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| trametinib and dabrafenib vs SOC | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | aaa | no data | | recurrence free survival | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| trametinib and dabrafenib vs vemurafenib | No demonstrated result suggested death (overall survival) by 31% (not demonstrated) suggested progression or death (progression free survival PFS) by 44% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | aaa | no data | | recurrence free survival | no data | | death (overall survival) | 0.69 [0.53 0.89] | p=0.04 | 0 | -18 | 1 | COMBI-V (Robert), | | progression or death (progression free survival PFS) | 0.56 [0.46 0.69] | p=0.04 | 0 | -18 | 1 | COMBI-V (Robert), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
